Could this Healthcare Stock really climb 1,712.62% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- November 6, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Is This The Most Overlooked Gold Investment Strategy of 2024?]( is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks. [Read this stunning report on a little-known gold royalty investment strategy]( --------------------------------------------------------------- [Esperion]( Symbol: [ESPR]( Recent Price: $1.03 Average Analyst Price Target: $12.40 (1,712.62%) Market Cap: $110.20M Last Year's EPS: -$0.79 Consensus EPS Forecast: -$0.63 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Dennis Ding, analyst at Jefferies, reiterates coverage on [Esperion (ESPR)]( in the Healthcare sector with a Buy rating and a price target of $12 (3 weeks ago). [TipRanks.com]( also reports that [Esperion]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.40 . The target pricing ranges from a high forecast of $4 down to a low forecast of $12. [Esperion (ESPR)](’s last closing price was $1.03 which would put the average price target at 1,712.62% upside. Here are 3rd party ratings for [ESPR](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 36% (91 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message ["ChatGPT Loophole" Could Spell Disastrous Miss For Cash Savers]( investors holding cash at record levels, Americans who sit this out could get left behind. According to one Silicon Valley insider, “this loophole is at the front of possible the biggest wealth transfer ever.” He’s estimated $20.6 trillion could be on the move. [Get the details now before its too late.]( --------------------------------------------------------------- [Science 37]( Symbol: [SNCE]( Recent Price: $0.40 Average Analyst Price Target: $5.00 (1,366.67%) Market Cap: $47.44M Last Year's EPS: -$0.11 Consensus EPS Forecast: -$0.12 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Frank Takkinen, analyst at Lake Street, reiterates coverage on [Science 37 (SNCE)]( in the Healthcare sector with a Buy rating and a price target of $1.5 (1 month ago). [TipRanks.com]( also reports that [Science 37]( currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.00 . The target pricing ranges from a high forecast of $2.5 down to a low forecast of $1. [Science 37 (SNCE)](’s last closing price was $0.40 which would put the average price target at 1,366.67% upside. Here are 3rd party ratings for [SNCE](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 28% (69 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Artelo Biosciences]( Symbol: [ARTL]( Recent Price: $1.33 Average Analyst Price Target: $18.33 (1,278.20%) Market Cap: $3.84M Last Year's EPS: $0.76 Consensus EPS Forecast: -$0.81 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Vernon Bernardino, analyst at H.C. Wainwright, reiterates coverage on [Artelo Biosciences (ARTL)]( in the Healthcare sector with a Buy rating and a price target of $5 (2 weeks ago). [TipRanks.com]( also reports that [Artelo Biosciences]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.33 . The target pricing ranges from a high forecast of $5 down to a low forecast of $10. [Artelo Biosciences (ARTL)](’s last closing price was $1.33 which would put the average price target at 1,278.20% upside. Here are 3rd party ratings for [ARTL](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 28% (69 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Nuwellis]( Symbol: [NUWE]( Recent Price: $0.75 Average Analyst Price Target: $10.00 (1,166.67%) Market Cap: $1.40M Last Year's EPS: -$5.09 Consensus EPS Forecast: -$4.02 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Anthony Vendetti, analyst at Maxim Group, reiterates coverage on [Nuwellis (NUWE)]( in the Consumer Defensive sector with a Buy rating and a price target of $10 (2 months ago). [TipRanks.com]( also reports that [Nuwellis]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10 down to a low forecast of $10. [Nuwellis (NUWE)](’s last closing price was $0.75 which would put the average price target at 1,166.67% upside. Here are 3rd party ratings for [NUWE](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 36% (90 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Clene]( Symbol: [CLNN]( Recent Price: $0.40 Average Analyst Price Target: $5.00 (1,137.32%) Market Cap: $51.89M Last Year's EPS: -$0.15 Consensus EPS Forecast: -$0.13 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Naz Rahman, analyst at Maxim Group, reiterates coverage on [Clene (CLNN)]( in the Healthcare sector with a Buy rating and a price target of $4 (4 weeks ago). [TipRanks.com]( also reports that [Clene]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.00 . The target pricing ranges from a high forecast of $7 down to a low forecast of $4. [Clene (CLNN)](’s last closing price was $0.40 which would put the average price target at 1,137.32% upside. Here are 3rd party ratings for [CLNN](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 28% (69 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Buffet and Pelosi Betting Millions on Apple Project?]( ��s next device lies at the center of an industry projected to grow 19,254%... and a tiny $5 stock is poised to soar 40X once it goes live. --------------------------------------------------------------- [Golden Minerals Co]( Symbol: [AUMN]( Recent Price: $0.90 Average Analyst Price Target: $10.95 (1,165.17%) Market Cap: $7.70M Last Year's EPS: -$0.5 Consensus EPS Forecast: -$0.5 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Siddharth Rajeev, analyst at Fundamental Research, reiterates coverage on [Golden Minerals Co (AUMN)]( in the Basic Materials sector with a Buy rating and a price target of $11.36 (2 months ago). [TipRanks.com]( also reports that [Golden Minerals Co]( currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.95 . The target pricing ranges from a high forecast of $9 down to a low forecast of $11.36. [Golden Minerals Co (AUMN)](’s last closing price was $0.90 which would put the average price target at 1,165.17% upside. Here are 3rd party ratings for [AUMN](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 30% (176 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Aethlon Medical]( Symbol: [AEMD]( Recent Price: $1.87 Average Analyst Price Target: $23.00 (1,129.95%) Market Cap: $4.64M Last Year's EPS: -$1.1 Consensus EPS Forecast: -$1.2 Expected Earnings Date: Nov 07 2023 Recent Analyst Action: Vernon Bernardino, analyst at H.C. Wainwright, reiterates coverage on [Aethlon Medical (AEMD)]( in the Healthcare sector with a Buy rating and a price target of $23 (1 week ago). [TipRanks.com]( also reports that [Aethlon Medical]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $23.00 . The target pricing ranges from a high forecast of $23 down to a low forecast of $23. [Aethlon Medical (AEMD)](’s last closing price was $1.87 which would put the average price target at 1,129.95% upside. Here are 3rd party ratings for [AEMD](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Gold Could Be Heading for Record Highs - But How to Play It?]( to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, InsideTraderAlerts.com InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software